{"id":"W2805592007","doi":"10.1016/s1470-2045(18)30351-6","title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2536,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Merck","keywords":"Medicine; Pembrolizumab; Sorafenib; Internal medicine; Clinical endpoint; Hepatocellular carcinoma; Adverse effect; Response Evaluation Criteria in Solid Tumors; Population; Oncology; Discontinuation; Clinical trial; Phases of clinical research; Surgery; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}